Groundbreaking Drug Discovery Technology Earns Giuseppe Barca the Prestigious Gordon Bell Prize!

SINGAPORE, Nov. 26, 2024 — In a stunning achievement that is set to change the face of drug discovery, QDX’s co-founder, Associate Professor Giuseppe Barca, has been awarded the 2024 ACM Gordon Bell Prize, often hailed as the "Nobel Prize of high-performance computing." This prestigious award honors his team’s innovative work in quantum chemistry simulations, which holds promise for transforming medicinal research and development.

The award-winning project, titled “Breaking the Million-Electron and 1 EFLOP/s Barriers: Biomolecular-Scale Ab Initio Molecular Dynamics Using MP2 Potentials,” was a collaborative effort that brought together brilliant minds from the Barca group at the University of Melbourne, the Australian National University, QDX, as well as Advanced Micro Devices, Inc., and Oak Ridge National Laboratory. By utilizing the cutting-edge Frontier supercomputer, the team has accomplished quantum-accurate simulations of biological systems at an unmatched scale, marking a historic shift in computational chemistry.

Under Barca's visionary leadership, this project is greatly enhancing QDX's capabilities in drug discovery. Their advanced simulation techniques are enabling highly precise predictions of molecular behavior, paving the way for the design of novel therapeutics with unprecedented accuracy and efficiency. “Receiving the Gordon Bell Prize is a tremendous honor," Barca commented. "This accolade underscores the transformative potential of high-performance computing in revolutionizing drug discovery processes. Our commitment at QDX remains firm in leveraging these advancements to fast-track the development of innovative therapies, ultimately improving patient outcomes.”

Loong Wang, Co-Founder and CEO of QDX, expressed his pride in Barca's recognition, emphasizing that it reflects the innovative essence of QDX. “Giuseppe's work exemplifies our mission to integrate leading-edge computational techniques into drug discovery, propelling us toward more effective treatments for patients around the globe. We’re thrilled about the future trajectory these advancements will open up in addressing complex diseases.”

QDX is poised to revolutionize drug discovery by integrating these state-of-the-art simulation methods into its platform. The company is engaging with pharmaceutical giants and tech startups across Australia, Singapore, and the USA to push the envelope even further. They aim to build upon the groundbreaking accomplishments made possible by Barca and his team's pioneering efforts, strengthening their computational drug discovery pipeline and developing the world's first in-silico simulation technology capable of harnessing exascale computing for precise therapeutic design.

Stay tuned, as this victory for QDX and Associate Professor Giuseppe Barca not only showcases the future of drug discovery but may also herald new treatments for some of medicine’s toughest challenges! For more information about QDX and its innovative approaches to drug discovery, visit www.qdx.co.

About QDX

QDX is a visionary drug discovery company that focuses on utilizing high-performance quantum simulations to accelerate the creation of new therapeutics. Established by specialists in life sciences, computational chemistry, and high-performance computing, QDX collaborates with partners worldwide to craft pioneering solutions for complex diseases.

About the ACM and the Gordon Bell Prize

The Association for Computing Machinery (ACM) is a leading organization in the computing field, dedicated to the advancement of knowledge and innovation. The annual Gordon Bell Prize celebrates extraordinary achievements in high-performance computing, honoring the legacy of Gordon Bell, a trailblazer in computer architecture and parallel computing.